Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Prostatic Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Neoplasm Metastasis 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Estrogen Receptor Positive 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Docetaxel 11Prednisone 10Leuprolide 10Magnetic Resonance Spectroscopy 9bicalutamide 8Radiotherapy 7Abiraterone Acetate 7Biopsy 6gallium 68 PSMA-11 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Surveys and Questionnaires 5Metformin 5Goserelin 5radium Ra 223 dichloride 4enzalutamide 4apalutamide 4Specimen Handling 4Injections 4Androgen Antagonists 4pembrolizumab 3orteronel 3cabazitaxel 3abiraterone 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3Pioglitazone 3Paclitaxel 3Exercise 3Brachytherapy 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Prostatic Neoplasms × copanlisib × Clear all
NCT06218667 2024-10-31

A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡